Trastuzumab vs Trastuzumab-Qyyp — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

HER2/neu Receptor Antagonist

Trastuzumab

Brand: HERZUMA

First FDA approval: 2017-02-10

HER2/neu Receptor Antagonist

Trastuzumab-Qyyp

Brand: Trazimera

First FDA approval: 2020-02-24

Lowest NADACAcquisition cost floor across all NDCs

—Per unit

Average NADACAcross all dosage forms and strengths

—

Generic manufacturersActive ANDA holders — FDA Orange Book

00 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$7.2MFull year

$18.3MFull year

Part D claims (CY24)Total fills, all strengths

1K224 beneficiaries

5K772 beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$5,192Per claim, all NDCs

$3,879Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

—Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

—None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

NoBrand-only